Filing Details
- Accession Number:
- 0001562180-23-002037
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-01 16:05:39
- Reporting Period:
- 2023-02-27
- Accepted Time:
- 2023-03-01 16:05:39
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1517022 | Akebia Therapeutics Inc. | AKBA | Pharmaceutical Preparations (2834) | 208756903 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1602396 | R. Nicole Hadas | C/O Akebia Therapeutics, Inc. 245 First Street Cambridge MA 02142 | Svp, Chief Legal Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-02-27 | 6,677 | $0.81 | 300,564 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
- Includes 1,500 shares of the Issuers common stock purchased on June 30, 2022, and 1,500 shares of the Issuers common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan.